Hot Performing Stocks To Invest In 2021

West Africa may not seem likely the location for the next big gold mining rush for investors in small cap gold stocks, but a couple of small caps in the West Africa mining space have been reporting progress this month.

Just today, small cap Avesoro Resources (OTCMKTS: ARSMF; TSE: ASO) announced production results for the quarter ended March 31, 2017 from its New Liberty Gold Mine in Liberia. The quarter saw continued improvement in both mining and processing operations as management continues the turnaround in operations at New Liberty. Total gold production for the Quarter was 14,906 ounces (as previously guided) while full year production guidance of 90,000 – 100,000 ounces was maintained as is previously advised cash cost guidance of US$750 – US$800 per ounce and all in sustaining costs (“AISC”) guidance of US$925 – US$975 per ounce of gold produced. The CEO commented:

Hot Performing Stocks To Invest In 2021: Five9, Inc.(FIVN)

Five9 is a pioneer and leading provider of cloud software for contact centers. Since our inception, we have exclusively focused on delivering our platform in the cloud and are disrupting a significantly large market by replacing legacy on-premise contact center systems. Contact centers are vital hubs of interaction between organizations and their customers and, therefore, are essential to delivering successful customer service, sales and marketing strategies. Our mission is to empower organizations to transform their contact centers into customer engagement centers of excellence, while improving business agility and significantly lowering the cost and complexity of their contact center operations. Our purpose-built, highly scalable and secure Virtual Contact Center (“VCC”) cloud platform delivers a comprehensive suite of easy-to-use applications that enable the breadth of contact center-related customer service, sales and marketing functions.   Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Five9 (FIVN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    Five9 Inc  (NASDAQ:FIVN)Q4 2018 Earnings Conference CallFeb. 19, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Performing Stocks To Invest In 2021: QuickLogic Corporation(QUIK)

QuickLogic Corporation, a fabless semiconductor company, develops and markets low power customizable semiconductor and software algorithm solutions for tablets, wearables, smartphones, and mobile enterprise markets. The company’s customer specific standard products incorporate its ArcticLink III S, ArcticLink III VX and BX, PolarPro 3, PolarPro II, and Eclipse II solution platforms, as well as packaging, proven system blocks, custom logic, sensor software algorithms, software drivers, and architecture consulting. Its products include pASIC 3, QuickRAM, and QuickPCI. The company markets and sells its products to original equipment manufacturers and original design manufacturers through a network of sales managers and distributors in North America, Europe, and Asia. QuickLogic Corporation was founded in 1988 and is headquartered in Sunnyvale, California.

Advisors’ Opinion:

  • [By Max Byerly]

    QuickLogic Co. (NASDAQ:QUIK)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $0.98 and last traded at $0.97, with a volume of 294 shares. The stock had previously closed at $0.99.

  • [By Logan Wallace]

    QuickLogic (NASDAQ: QUIK) and SemiLEDs (NASDAQ:LEDS) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on QuickLogic (QUIK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Performing Stocks To Invest In 2021: Qiagen N.V.(QGEN)

QIAGEN is a global leader in Sample to Insight solutions that transform biological samples into valuable molecular insights. Our vision is to make improvements in life possible by enabling our customers in four broad classes – Molecular Diagnostics, Applied Testing, Pharma and Academia – to achieve outstanding success and breakthroughs using reliable and efficient Sample to Insight solutions. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Our solutions support more than 500,000 customers worldwide in generating insights into the molecular building blocks of life. More than two billion biological samples have been prepared or analyzed using QIAGEN sample technologies. Our proven solutions are providing answers in hospitals and laboratories worldwide, integrated with bioinformatics to make sense of the increasing volumes and complexity of data.   Advisors’ Opinion:

  • [By Shane Hupp]

    Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.40. The business had revenue of $403.20 million during the quarter, compared to analysts’ expectations of $409.32 million. Qiagen had a net margin of 12.68% and a return on equity of 12.15%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 EPS. Research analysts expect that Qiagen NV will post 1.45 EPS for the current fiscal year.

    WARNING: “Castleark Management LLC Sells 78,050 Shares of Qiagen NV (QGEN)” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at www.tickerreport.com/banking-finance/4205670/castleark-management-llc-sells-78050-shares-of-qiagen-nv-qgen.html.

    Qiagen Profile

  • [By Keith Speights]

    Qiagen (NYSE:QGEN) provides technology used in analyzing liquid biopsies. The company’s CEO, Peer Schatz, specifically cited processing samples for liquid biopsy as a key growth area for Qiagen in his remarks during the company’s Q3 conference call in October.

  • [By Motley Fool Transcribing]

    Qiagen N.V. (NYSE:QGEN) Q4 2018 Earnings Conference CallFeb. 5, 2019 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    WARNING: “Qiagen (QGEN) Releases FY19 Earnings Guidance” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at www.tickerreport.com/banking-finance/4125869/qiagen-qgen-releases-fy19-earnings-guidance.html.

Hot Performing Stocks To Invest In 2021: Pluristem Therapeutics Inc.(PSTI)

Pluristem Therapeutics Inc., a bio-therapeutic company, engages in the research, development, and commercialization of standardized cell therapy products for the treatment of life threatening diseases. The company?s products are derived from human placenta, a non-controversial, non-embryonic, adult cell source. Its Placental adherent stromal cells are grown in the company’s proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease. It also offers various product candidates for diabetic foot ulcers, adjuvant hip replacement surgery, athletic injuries, inflammatory bowel disease, multiple sclerosis, neuropathic pain, ischemic stroke, adjuvant for UCB transplantation, and radiation exposure. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Pluristem Therapeutics alerts:

    Pluristem Therapeutics Inc. (PSTI) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com) Head-To-Head Analysis: Pluristem Therapeutics (PSTI) & Amgen (AMGN) (americanbankingnews.com) Pre-Eclampsia Treatment Market Outlook 2025, Global Opportunity & Growth Analysis, Key Players – Alnylam … (menafn.com) Flickering Three Stocks: Golden Star Resources Ltd. (NYSE:GSS), Pluristem Therapeutics Inc. (NASDAQ:PSTI … (thestreetpoint.com) Pluristem Therapeutics Inc. (PSTI) moves -0.72% higher to SMA-50 (nasdaqplace.com)

    Pluristem Therapeutics stock traded up $0.01 during trading hours on Monday, reaching $1.37. The stock had a trading volume of 3,754 shares, compared to its average volume of 201,217. The firm has a market cap of $150.78 million, a PE ratio of -4.28 and a beta of 0.32. Pluristem Therapeutics has a 52 week low of $1.12 and a 52 week high of $2.12.

  • [By Ethan Ryder]

    Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) have earned an average recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $4.13.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Momenta Pharmaceuticals (NASDAQ: MNTA) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Hot Performing Stocks To Invest In 2021: HCP, Inc.(HCP)

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Irvine, California with additional office in Nashville and San Francisco.

Advisors’ Opinion:

  • [By Logan Wallace]

    HCP, Inc. (NYSE:HCP) – Equities researchers at Capital One Financial increased their Q1 2019 earnings estimates for HCP in a research report issued to clients and investors on Tuesday, March 12th. Capital One Financial analyst D. Bernstein now expects that the real estate investment trust will post earnings per share of $0.43 for the quarter, up from their previous estimate of $0.42. Capital One Financial also issued estimates for HCP’s Q2 2019 earnings at $0.42 EPS, Q3 2019 earnings at $0.42 EPS, FY2019 earnings at $1.70 EPS, Q1 2020 earnings at $0.44 EPS, Q2 2020 earnings at $0.45 EPS, Q3 2020 earnings at $0.44 EPS, Q4 2020 earnings at $0.44 EPS and FY2020 earnings at $1.77 EPS.

  • [By Motley Fool Transcription]

    HCP, Inc. (NYSE:HCP)Q4 2018 Earnings Conference CallFeb. 14, 2019, 12:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Reuben Gregg Brewer]

    HCP (NYSE:HCP) and Physicians Realty Trust (NYSE:DOC) both advanced roughly 13%, while Omega Healthcare Investors (NYSE:OHI) jumped a little over 14%. Ventas (NYSE:VTR) and Welltower (NYSE:WELL) joined the party, too, up 10% and 11%, respectively.

  • [By Stephan Byrd]

    JPMorgan Chase & Co. lowered shares of HCP (NYSE:HCP) from an overweight rating to a neutral rating in a research report report published on Friday, Marketbeat.com reports.

Leave a Reply

Your email address will not be published. Required fields are marked *